135 related articles for article (PubMed ID: 35652795)
1. The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing.
Xu J; Hao Z; Chen X; Hong M; Muyey DM; Chen X; Wang H
Leuk Lymphoma; 2022 Oct; 63(10):2321-2329. PubMed ID: 35652795
[TBL] [Abstract][Full Text] [Related]
2. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract][Full Text] [Related]
3. Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia.
Richardson DR; Swoboda DM; Moore DT; Johnson SM; Chan O; Galeotti J; Esparza S; Hussaini MO; Van Deventer H; Foster MC; Coombs CC; Montgomery ND; Sallman DA; Zeidner JF
Am J Hematol; 2021 Apr; 96(4):462-470. PubMed ID: 33502020
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing reveals gene mutations landscape and clonal evolution in patients with acute myeloid leukemia.
Chen X; Zhu H; Qiao C; Zhao S; Liu L; Wang Y; Jin H; Qian S; Wu Y
Hematology; 2021 Dec; 26(1):111-122. PubMed ID: 33491606
[TBL] [Abstract][Full Text] [Related]
5. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
[No Abstract] [Full Text] [Related]
6. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.
Ohgami RS; Ma L; Merker JD; Gotlib JR; Schrijver I; Zehnder JL; Arber DA
Mod Pathol; 2015 May; 28(5):706-14. PubMed ID: 25412851
[TBL] [Abstract][Full Text] [Related]
7. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
[TBL] [Abstract][Full Text] [Related]
8. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated
Nguyen L; Zhang X; Roberts E; Yun S; McGraw K; Abraham I; Song J; Braswell D; Qin D; Sallman DA; Lancet JE; List AF; Moscinski LC; Padron E; Zhang L
Leuk Lymphoma; 2020 Jun; 61(6):1395-1405. PubMed ID: 32091281
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique.
Wang RQ; Chen CJ; Jing Y; Qin JY; Li Y; Chen GF; Zhou W; Li YH; Wang J; Li DW; Zhao HM; Wang BH; Wang LL; Wang H; Wang MZ; Gao XN; Yu L
Cancer Med; 2020 Nov; 9(22):8457-8467. PubMed ID: 32970934
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and prognostic study of adult acute myeloid leukemia patients with
Lin Y; Wang Y; Zheng Y; Wang Z; Wang Y; Wang S
Hematology; 2020 Dec; 25(1):446-456. PubMed ID: 33250015
[No Abstract] [Full Text] [Related]
11. ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.
Paschka P; Schlenk RF; Gaidzik VI; Herzig JK; Aulitzky T; Bullinger L; Späth D; Teleanu V; Kündgen A; Köhne CH; Brossart P; Held G; Horst HA; Ringhoffer M; Götze K; Nachbaur D; Kindler T; Heuser M; Thol F; Ganser A; Döhner H; Döhner K
Haematologica; 2015 Mar; 100(3):324-30. PubMed ID: 25596267
[TBL] [Abstract][Full Text] [Related]
12. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1.
Quesada AE; Montalban-Bravo G; Luthra R; Patel KP; Sasaki K; Bueso-Ramos CE; Khoury JD; Routbort MJ; Bassett R; Hidalgo-Lopez JE; Zhao C; Lin P; Loghavi S; Ok CY; Kadia T; DiNardo CD; Kantarjian H; Garcia-Manero G; Kanagal-Shamanna R
Mod Pathol; 2020 Sep; 33(9):1678-1689. PubMed ID: 32238878
[TBL] [Abstract][Full Text] [Related]
13. PTPN11 mutations in adult acute myeloid leukaemia: Prevalence and clinical implications in the context of NPM1 mutation.
Liu J; Qin W; Wang B; Wang Z; Hua H; Zhou F; Jia Z; Wu P; Chao H; Lu X
Leuk Res; 2022 Jul; 118():106859. PubMed ID: 35617714
[TBL] [Abstract][Full Text] [Related]
14. TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.
Tian X; Xu Y; Yin J; Tian H; Chen S; Wu D; Sun A
Int J Hematol; 2014 Jul; 100(1):96-104. PubMed ID: 24859829
[TBL] [Abstract][Full Text] [Related]
15. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
[TBL] [Abstract][Full Text] [Related]
16. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
[TBL] [Abstract][Full Text] [Related]
17. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
[TBL] [Abstract][Full Text] [Related]
18. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
19. The correlation of next-generation sequencing-based genotypic profiles with clinicopathologic characteristics in NPM1-mutated acute myeloid leukemia.
Wang B; Yang B; Wu W; Liu X; Li H
BMC Cancer; 2021 Jul; 21(1):788. PubMed ID: 34238278
[TBL] [Abstract][Full Text] [Related]
20. Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine-based chemotherapy.
Ni J; Hong J; Long Z; Li Q; Xia R; Zeng Q
Int J Lab Hematol; 2020 Dec; 42(6):849-857. PubMed ID: 32730663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
